Israel · Delayed Price · Currency is ILS · Price in ILA Nextgen Biomed Statistics
Total Valuation
Nextgen Biomed has a market cap or net worth of ILS 10.12 million. The enterprise value is 11.22 million.
| Market Cap | 10.12M |
| Enterprise Value | 11.22M |
Important Dates
The next estimated earnings date is Monday, February 2, 2026.
| Earnings Date | Feb 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nextgen Biomed has 14.80 million shares outstanding. The number of shares has increased by 37.05% in one year.
| Current Share Class | 14.80M |
| Shares Outstanding | 14.80M |
| Shares Change (YoY) | +37.05% |
| Shares Change (QoQ) | +22.60% |
| Owned by Insiders (%) | 17.44% |
| Owned by Institutions (%) | 7.03% |
| Float | 12.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.01 |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.27 |
| Interest Coverage | -35.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -576.15% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 110.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.18M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.44% in the last 52 weeks. The beta is 0.71, so Nextgen Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +2.44% |
| 50-Day Moving Average | 57.26 |
| 200-Day Moving Average | 59.92 |
| Relative Strength Index (RSI) | 63.74 |
| Average Volume (20 Days) | 132,844 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.62M |
| Pretax Income | -10.88M |
| Net Income | -9.55M |
| EBITDA | -10.46M |
| EBIT | -10.62M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
The company has 300,000 in cash and 2.85 million in debt, with a net cash position of -2.55 million or -0.17 per share.
| Cash & Cash Equivalents | 300,000 |
| Total Debt | 2.85M |
| Net Cash | -2.55M |
| Net Cash Per Share | -0.17 |
| Equity (Book Value) | -9.72M |
| Book Value Per Share | -0.73 |
| Working Capital | -10.53M |
Cash Flow
In the last 12 months, operating cash flow was -2.21 million and capital expenditures -28,000, giving a free cash flow of -2.24 million.
| Operating Cash Flow | -2.21M |
| Capital Expenditures | -28,000 |
| Free Cash Flow | -2.24M |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nextgen Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.05% |
| Shareholder Yield | -37.05% |
| Earnings Yield | -94.34% |
| FCF Yield | -22.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 3, 2023. It was a reverse split with a ratio of 0.1666666667.
| Last Split Date | Sep 3, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |